MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
MediciNova (NASDAQ:MNOV) announced that its Phase 2b/3 COMBAT-ALS clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients will be featured in a poster presentation at the 36th International Symposium on ALS/MND. The symposium will take place from December 5-7, 2025 in San Diego, CA.
The presentation, titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics," has been assigned Paper Number 228 and falls under the Clinical Trial and Trial Design theme.
MediciNova (NASDAQ:MNOV) ha annunciato che il suo studio di fase 2b/3 COMBAT-ALS di MN-166 (ibudilast) nei pazienti affetti da Sclerosi Laterale Amiotrofica (ALS) sarà presentato in una poster al 36° Simposio Internazionale sull'ALS/MND. Lo symposium si svolgerà dal 5 al 7 dicembre 2025 a San Diego, CA.
La presentazione, intitolata "COMBAT-ALS Studio di fase 2b/3 di MN-166 (Ibudilast) in ALS: Aggiornamento dello studio e caratteristiche di base", è stata assegnata il Paper Number 228 e rientra nel tema Studio Clinico e Progettazione dello Studio.
MediciNova (NASDAQ:MNOV) anunció que su ensayo de fase 2b/3 COMBAT-ALS de MN-166 (ibudilast) en pacientes con esclerosis lateral amiotrófica (ELA) será presentado en un cartel en el 36º Simposio Internacional sobre ELA/MND. El simposio se celebrará del 5 al 7 de diciembre de 2025 en San Diego, CA.
La presentación, titulada "COMBAT-ALS, ensayo de fase 2b/3 de MN-166 (Ibudilast) en ELA: Actualización del ensayo y características basales", ha sido asignado el Paper Number 228 y se enmarca dentro del tema Ensayo Clínico y Diseño de Ensayos.
MediciNova (NASDAQ:MNOV)는 MN-166(ibudilast)을 이용한 ALS 환자 대상의 2b/3상 COMBAT-ALS 임상시험이 ALS/MND 국제학술대회 36차 포스터로 발표될 것이라고 발표했다. 이 학술대회는 2025년 12월 5–7일에 캘리포니아 주 샌디에이고에서 개최된다.
발표 제목은 "COMBAT-ALS MN-166(이부디라스트) ALS에서의 2b/3상: 시험 업데이트 및 기저 특성"이며, Paper Number 228로 지정되었고 임상시험 및 시험 설계 주제에 해당한다.
MediciNova (NASDAQ:MNOV) a annoncé que son essai de phase 2b/3 COMBAT-ALS de MN-166 (ibudilast) chez des patients atteints de sclérose latérale amyotrophique (SLA) sera présenté sous forme d'affiche lors du 36e Symposium international sur l'ALS/MND. Le symposium se déroulera du 5 au 7 décembre 2025 à San Diego, CA.
La présentation, intitulée "COMBAT-ALS, essai de phase 2b/3 de MN-166 (Ibudilast) dans la SLA : Mise à jour de l'essai et caractéristiques basales", a reçu le Paper Number 228 et s'inscrit dans le thème Essai clinique et Conception des essais.
MediciNova (NASDAQ:MNOV) gab anunció, dass seine Phase-2b/3-Studie COMBAT-ALS von MN-166 (Ibudilast) bei ALS-Patienten in einer Posterpräsentation auf dem 36. Internationalen Symposium über ALS/MND vorgestellt wird. Das Symposium findet vom 5. bis 7. Dezember 2025 in San Diego, CA, statt.
Die Präsentation mit dem Titel "COMBAT-ALS Phase-2b/3-Studie von MN-166 (Ibudilast) bei ALS: Studienaktualisierung und Baseline-Eigenschaften" hat die Paper-Nummer 228 erhalten und gehört zum Thema Klinische Studie und Design der Studie.
MediciNova (NASDAQ:MNOV) يعلن أن تجربة المرحلة 2b/3 COMBAT-ALS لـ MN-166 (ibudilast) في مرضى التصلّب الجانبي الضموري (ALS) ستُقدَّم في ملصَق ضمن الندوة الدولية الـ 36 لـALS/MND. ستعقد الندوة من 5 إلى 7 ديسمبر 2025 في سان دييغو، كاليفورنيا.
العرض التقديمي بعنوان "اختبار COMBAT-ALS المرحلة 2b/3 لـ MN-166 (Ibudilast) في ALS: تحديث التجربة وخصائص الأساس"، عُيّن له رقم الورقة 228 ويندرج ضمن موضوع التجربة السريرية وتصميم التجربة.
MediciNova (NASDAQ:MNOV) 宣布，其在肌萎缩性侧索硬化症（ALS）患者中的 MN-166（ibudilast） Phase 2b/3 COMBAT-ALS 临床试验将以海报形式在 第36届国际ALS/MND学术研讨会上展示。该研讨会将于 2025年12月5-7日在美国加利福尼亚州圣地亚哥举行。
此次展示题为“COMBAT-ALS MN-166（Ibudilast）在ALS中的2b/3期试验：试验更新与基线特征”，已分配论文编号 228，并归属于 临床试验与试验设计主题。
- None.
- None.
LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36th International Symposium on ALS/MND to be held December 5-7, 2025 in San Diego, CA.
The presentation details are as follows:
Paper Number: 228
Title: COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics
Theme: Clinical Trial and Trial Design
About MN-166 (ibudilast)
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ
When and where will MediciNova (MNOV) present its COMBAT-ALS trial results?
What is the focus of MediciNova's (MNOV) COMBAT-ALS clinical trial presentation?
What type of presentation will MediciNova (MNOV) give at the ALS/MND Symposium?
What drug is being studied in MediciNova's (MNOV) COMBAT-ALS trial?
